Share on StockTwits

OncoGenex Pharmaceuticals (NASDAQ:OGXI) CEO Scott Daniel Cormack sold 18,341 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $3.17, for a total transaction of $58,140.97. Following the transaction, the chief executive officer now directly owns 84,139 shares of the company’s stock, valued at approximately $266,721. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of OncoGenex Pharmaceuticals (NASDAQ:OGXI) traded up 0.61% on Thursday, hitting $3.30. 102,958 shares of the company’s stock traded hands. OncoGenex Pharmaceuticals has a one year low of $2.86 and a one year high of $14.25. The stock’s 50-day moving average is $3.24 and its 200-day moving average is $7.04. The company’s market cap is $69.8 million. OncoGenex Pharmaceuticals also was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totalling 305,595 shares, a decrease of 45.7% from the July 15th total of 562,692 shares. Based on an average daily volume of 113,186 shares, the short-interest ratio is presently 2.7 days. Currently, 1.6% of the shares of the company are short sold.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) last announced its earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. Analysts expect that OncoGenex Pharmaceuticals will post $-1.75 EPS for the current fiscal year.

OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.